Released Nov 12, 2026, after the close
10-Q filed Nov 12, 2026, 43 days after period end · 0001193125-26-458593
What the release said
Spero in-licensed SP001 from affiliates of Innovent Biologics, Inc., obtaining exclusive worldwide rights, excluding Greater China (Mainland China, Hong Kong, Macau, and Taiwan), to research, develop, manufacture, and commercialize the antibody.
In July 2026 Spero in-licensed SP001 from affiliates of Innovent Biologics, and R&D expenses for the third quarter of 2026 were $38.2 million, up from $8.6 million, primarily due to the $35M upfront payment to Innovent.¶1¶2
In July 2026 Spero closed a $105 million non-recourse, non-dilutive milestone and royalty financing with affiliates of HealthCare Royalty Partners, a business of KKR, in exchange for a portion of anticipated Utebzi payments owed by GSK.¶3
Spero reported a net loss of $44.3 million for the third quarter of 2026, compared to a net loss of $7.4 million for the third quarter of 2025, and no revenue for the third quarter of 2026 versus $5.4 million a year earlier.¶4¶5
As of September 30, 2026, cash and cash equivalents were $107.9 million, and Spero expects them to fund operations into the second half of 2029.¶6
- Research and development expenses, Q3 2026
- $38.2 million for the third quarter of 2026, compared to the same period in 2025¶2
- Net loss, Q3 2026
- $44.3 million¶4
- Diluted net loss per share, Q3 2026
- $0.76¶4
- General and administrative expenses, Q3 2026
- $3.7 million for the third quarter of 2026, compared to $4.2 million for the same period in 2025¶7
- Cash and cash equivalents
- $107.9 million as of September 30, 2026¶6
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $65.00K | $218.00K |
| Net Income | -$44.28M | -$7.38M | -$17.15M | -$3.20M |
| EPS Diluted | -$0.76 | -$0.13 | -$0.32 | -$0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR